As filed with the Securities and Exchange Commission on October 13, 2020
Registration Statement on Form S-8 (No. 333-206307)
Registration Statement on Form S-8 (No. 333-210142)
Registration Statement on Form S-8 (No. 333-216724)
Registration Statement on Form S-8 (No. 333-223102)
Registration Statement on Form S-8 (No. 333-229980)
Registration Statement on Form S-8 (No. 333-236703)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-206307)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-210142)
Post-Effective Amendment No. 1
to Registration Statement on Form S-8 (No. 333-216724)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-223102)
Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (No. 333-229980)
Post-Effective Amendment No. 1
to Registration Statement on Form S-8 (No. 333-236703)
Under
the
Securities Act of 1933
AIMMUNE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
45-2748244
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
8000 Marina Blvd, Suite 300
Brisbane, CA 94005
(650)
614-5220
(Address, including zip code, and telephone number, including area code, of
Registrants principal executive offices)
2013 Stock Plan, as amended
2015 Equity Incentive Award Plan
2015 Employee Stock Purchase Plan
(Full title of the Plan)
|
|
|
Jayson Dallas, M.D.
President and Chief Executive Officer
Aimmune Therapeutics, Inc.
8000 Marina Blvd, Suite 300
Brisbane, CA 94005
(650) 614-5220
|
|
Copies to:
Patrick Pohlen
Luke
Bergstrom
Brett Urig
Latham & Watkins LLP
505 Montgomery Street, Suite 2000
San Francisco, CA 94111
Telephone: (415) 391-0600
Facsimile: (415) 395-8095
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company or emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐